Skip to main content

Table 2 EBV and CMV seroprevalence and antibodies titers in MS patients and controls

From: HLA alleles modulate EBV viral load in multiple sclerosis

 

Healthy controls (HC)

Multiple sclerosis patients (MS)

Relapsing–remitting MS patients (RR-MS)

Progressive MS patients (P-MS)

EBV seroprevalence (%)

100

100

100

100

EBNA-1 IgG (U/ml)

782.55 (627.82–910.95)

1009.23* (782.79–1383.37)

1139.00* (782.70–1452.15)

937.29** (828.82–1191.21)

VCA Ab (U/ml)

375.54 (144.77–625.19)

969.07** (511.62–1340.41)

1146.45** (560.95–1407.95)

885.15 (277.02–1050.24)

CMV seroprevalence (%)

64.3

70.2

69.7

71.2

CMV IgG (U/ml)

58.40 (38.15–84.47)

83.40 (46.33–119.56)

80.87 (46.78–124.58)

86.68 (55.04–112.95)

  1. Data are expressed as medians and (interquartile range)
  2. EBV Epstein-Barr Virus, CMV cytomegalovirus, EBNA1 EBV nuclear antigen 1, VCA viral capsid antigen, IgG immunoglobulin G, VL viral load
  3. * p < 0.0001 vs. HC
  4. ** p < 0.05 vs. HC